Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response

Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model

(2014) D. W. Denning et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model

(2014) M. Siopi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhibitory and Fungicidal Effects of Antifungal Drugs against Aspergillus Species in the Presence of Serum

(2013) Antigoni Elefanti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroPharmacokinetic/Pharmacodynamic Modeling of Voriconazole Activity against Aspergillus Species in a NewIn VitroDynamic Model

(2012) R. Al-Saigh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

(2010) E. Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Study on the Efficacy of Liposomal Amphotericin B and Voriconazole in a Murine Pulmonary Aspergillosis Model

(2009) Koji Takemoto et al.   CHEMOTHERAPY